WO2023209687 - CAS9 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2023/209687
Publication Date
02.11.2023
International Application No.
PCT/IB2023/054484
International Filing Date
29.04.2023
Title **
[English]
CAS9 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS CAS9 ET LEURS UTILISATIONS
Applicants **
CRISPR THERAPEUTICS AG
Inventors
KULMAN, John
KUMAR, Lalit
SAKHI, Aditi
Priority Data
63/336,968
29.04.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4712 | |
| EPO | Filing, Examination, Granting | 62589 | |
| Japan | Filing, Examination, Granting | 4069 | |
| South Korea | Filing, Examination, Granting | 5786 | |
| USA | Filing, Examination, Granting | 19240 |
Total:
96,396
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided include antibodies or fragments thereof having specificity to a Cas9 protein. The present disclosure also relates to compositions, kits and methods of using the antibodies or fragments thereof, for example for detecting Cas9 in a biological sample.[French]
L'invention concerne des anticorps ou des fragments de ceux-ci ayant une spécificité vis-à-vis d'une protéine Cas9. La présente divulgation concerne également des compositions, des kits et des procédés d'utilisation des anticorps ou des fragments de ceux-ci, par exemple pour détecter Cas9 dans un échantillon biologique.